版本:
中国

BRIEF-Lion Biotechnologies says first patient dosed in 2nd cohort of ln-144 phase 2 trial for metastatic melanoma

May 19 Lion Biotechnologies Inc:

* Lion Biotechnologies announces first patient dosed in second cohort of ln-144 phase 2 trial for metastatic melanoma

* Lion Biotechnologies -phase 2 multicenter, three-cohort study to assess safety & efficacy of ln-144 for treatment of patients with metastatic melanoma Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐